Lucyna Antkiewicz-Michaluk

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6540470/publications.pdf

Version: 2024-02-01

99 papers

2,005 citations

218381 26 h-index 315357 38 g-index

104 all docs

104 docs citations

104 times ranked 1667 citing authors

#	Article	IF	CITATIONS
1	Different action on dopamine catabolic pathways of two endogenous 1,2,3,4-tetrahydroisoquinolines with similar antidopaminergic properties. Journal of Neurochemistry, 2001, 78, 100-108.	2.1	79
2	Chronic administration of antidepressant drugs increases the density of cortical [3H]prazosin binding sites in the rat. Brain Research, 1984, 310, 360-362.	1.1	74
3	Antidepressant-like Effect of Tetrahydroisoquinoline Amines in the Animal Model of Depressive Disorder Induced by Repeated Administration of a Low Dose of Reserpine: Behavioral and Neurochemical Studies in the Rat. Neurotoxicity Research, 2014, 26, 85-98.	1.3	70
4	Effects of various Ca2+ channel antagonists on morphine analgesia, tolerance and dependence, and on blood pressure in the rat. European Journal of Pharmacology, 1998, 352, 189-197.	1.7	68
5	The mechanism of neuroprotective action of natural compounds. Pharmacological Reports, 2017, 69, 851-860.	1.5	68
6	Reduction of morphine dependence and potentiation of analgesia by chronic co-administration of nifedipine. Psychopharmacology, 1993, 111, 457-464.	1.5	55
7	Behavioural and biochemical studies of citalopram and WAY 100635 in rat chronic mild stress model. Pharmacology Biochemistry and Behavior, 2002, 72, 465-474.	1.3	50
8	Protective effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline against dopaminergic neurodegeneration in the extrapyramidal structures produced by intracerebral injection of rotenone. International Journal of Neuropsychopharmacology, 2004, 7, 155-163.	1.0	50
9	The mechanism of 1,2,3,4-tetrahydroisoquinolines neuroprotection: the importance of free radicals scavenging properties and inhibition of glutamate-induced excitotoxicity. Journal of Neurochemistry, 2006, 97, 846-856.	2.1	50
10	5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine. Journal of Pharmacy and Pharmacology, 2011, 32, 220-222.	1.2	46
11	Role of calcium channels in effects of antidepressant drugs on responsiveness to pain. Psychopharmacology, 1991, 105, 269-274.	1.5	45
12	A possible physiological role for cerebral tetrahydroisoquinolines. Neurotoxicity Research, 2003, 5, 147-155.	1.3	41
13	1-Methyl-1,2,3,4-tetrahydroisoquinoline protects against rotenone-induced mortality and biochemical changes in rat brain. European Journal of Pharmacology, 2003, 466, 263-269.	1.7	41
14	Synthesis, antiarrhythmic, and antihypertensive effects of novel 1-substituted pyrrolidin-2-one and pyrrolidine derivatives with adrenolytic activity. European Journal of Medicinal Chemistry, 2002, 37, 183-195.	2.6	39
15	Isobolographic analysis of interactions between 1-methyl-1,2,3,4-tetrahydroisoquinoline and four conventional antiepileptic drugs in the mouse maximal electroshock-induced seizure model. European Journal of Pharmacology, 2009, 602, 298-305.	1.7	39
16	1-Methyl-1,2,3,4-Tetrahydroisoquinoline, an Endogenous Amine with Unexpected Mechanism of Action: New Vistas of Therapeutic Application. Neurotoxicity Research, 2014, 25, 1-12.	1.3	37
17	Cortical dihydropyridine binding sites and a behavioral syndrome in morphine-abstinent rats. European Journal of Pharmacology, 1990, 180, 129-135.	1.7	36
18	Antidepressant-like effect of the selective 5-HT1B receptor agonist CP 94253: A possible mechanism of action. European Journal of Pharmacology, 2005, 516, 46-50.	1.7	36

#	Article	IF	Citations
19	Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology. Biological Psychiatry, 1997, 42, 514-518.	0.7	35
20	Inhibition of rodent brain monoamine oxidase and tyrosine hydroxylase by endogenous compounds - 1,2,3,4-tetrahydro-isoquinoline alkaloids. Polish Journal of Pharmacology, 2004, 56, 727-34.	0.3	35
21	Anticonvulsant activity of some xanthone derivatives. Bioorganic and Medicinal Chemistry, 2008, 16, 7234-7244.	1.4	34
22	Different effects of intranigral and intrastriatal administration of the proteasome inhibitor lactacystin on typical neurochemical and histological markers of Parkinson's disease in rats. Neurochemistry International, 2011, 58, 839-849.	1.9	34
23	Dopamine receptors in the striatum and limbic system of various strains of mice: Relation to differences in responses to apomorphine. Pharmacology Biochemistry and Behavior, 1982, 17, 1115-1118.	1.3	33
24	Increase in rat cortical [3H]naloxone binding site density after chronic administration of antidepressant agents. European Journal of Pharmacology, 1984, 102, 179-181.	1.7	32
25	1-Methyl-1,2,3,4-tetrahydroisoquinoline Antagonizes a Rise in Brain Dopamine Metabolism, Glutamate Release in Frontal Cortex and Locomotor Hyperactivity Produced by MK-801 but not the Disruptions of Prepulse Inhibition, and Impairment of Working Memory in Rat. Neurotoxicity Research, 2009, 16, 390-407.	1.3	32
26	The Effect of Chronic Mild Stress and Imipramine on the Markers of Oxidative Stress and Antioxidant System in Rat Liver. Neurotoxicity Research, 2016, 30, 173-184.	1.3	30
27	Chronic impairment of the vagus nerve function leads to inhibition of dopamine but not serotonin neurons in rat brain structures. Pharmacological Reports, 2012, 64, 1359-1367.	1.5	29
28	Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine. European Journal of Medicinal Chemistry, 2002, 37, 845-853.	2.6	27
29	Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine. European Journal of Medicinal Chemistry, 2002, 37, 761-772.	2.6	27
30	3-Methoxytyramine, an extraneuronal dopamine metabolite plays a physiological role in the brain as an inhibitory regulator of catecholaminergic activity. European Journal of Pharmacology, 2008, 599, 32-35.	1.7	25
31	Comparison of the effects of 1MeTIQ and olanzapine on performance in the elevated plus maze test and monoamine metabolism in the brain after ketamine treatment. Pharmacology Biochemistry and Behavior, 2019, $181, 17-27$.	1.3	24
32	Synthesis and pharmacological activity of new carbonyl derivatives of 1-aryl-2-iminoimidazolidine Part 1. Synthesis and pharmacological activity of chain derivatives of 1-aryl-2-iminoimidazolidine containing urea moiety. European Journal of Medicinal Chemistry, 2001, 36, 783-797.	2.6	23
33	1-Benzyl-1,2,3,4-Tetrahydroisoquinoline, an Endogenous Parkinsonism-Inducing Toxin, Strongly Potentiates MAO-Dependent Dopamine Oxidation and Impairs Dopamine Release: Ex vivo and In vivo Neurochemical Studies. Neurotoxicity Research, 2009, 15, 15-23.	1.3	22
34	Antidepressant-like activity of the endogenous amine, 1-methyl-1,2,3,4-tetrahydroisoquinoline in the behavioral despair test in the rat, and its neurochemical correlates: A comparison with the classical antidepressant, imipramine. European Journal of Pharmacology, 2013, 700, 110-117.	1.7	21
35	Effect of repetitive electroconvulsive treatment on sensitivity to pain and on [3H]nitrendipine binding sites in cortical and hippocampal membranes. Psychopharmacology, 1990, 101, 240-243.	1.5	20
36	Endogenous risk factors in Parkinson's disease: dopamine and tetrahydroisoquinolines. Polish Journal of Pharmacology, 2002, 54, 567-72.	0.3	20

#	Article	IF	CITATIONS
37	Purification of a novel DBI processing product, DBI39–75, and characterization of its binding site in rat brain. Regulatory Peptides, 1994, 50, 29-35.	1.9	19
38	The Ca2+ Channel Blockade Changes the Behavioral and Biochemical Effects of Immobilization Stress. Neuropsychopharmacology, 1999, 20, 248-254.	2.8	19
39	Salsolinol, an Endogenous Compound Triggers a Two-Phase Opposing Action in the Central Nervous System. Neurotoxicity Research, 2015, 27, 300-313.	1.3	19
40	1-Methyl-1,2,3,4-tetrahydroisoquinoline enhances the anticonvulsant action of carbamazepine and valproate in the mouse maximal electroshock seizure model. Neuropharmacology, 2006, 50, 133-142.	2.0	18
41	Anticonvulsant evaluation of aminoalkanol derivatives of 2- and 4-methylxanthone. Bioorganic and Medicinal Chemistry, 2013, 21, 1190-1198.	1.4	17
42	Resilient Phenotype in Chronic Mild Stress Paradigm Is Associated with Altered Expression Levels of miR-18a-5p and Serotonin 5-HT1a Receptor in Dorsal Part of the Hippocampus. Molecular Neurobiology, 2019, 56, 7680-7693.	1.9	17
43	Search for New Antiarrhythmic and Hypotensive Compounds. Synthesis, Antiarrhythmic, Antihypertensive, and α-Adrenoceptor Blocking Activity of Novel 1-[(2-Hydroxy-3-amino)]-propylpyrrolidin-2-one Derivatives. Archiv Der Pharmazie, 1997, 330, 225-231.	2.1	16
44	1-Methyl-1,2,3,4-tetrahydroisoquinoline, an Endogenous Neuroprotectant and MAO Inhibitor with Antidepressant-Like Properties in the Rat. Neurotoxicity Research, 2014, 25, 323-334.	1.3	16
45	Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats. Naunyn-Schmiedeberg's Archives of Pharmacology, 2016, 389, 839-849.	1.4	16
46	Acute treatment with doxorubicin induced neurochemical impairment of the function of dopamine system in rat brain structures. Pharmacological Reports, 2016, 68, 627-630.	1,5	16
47	Nicotine produces antidepressant-like actions: Behavioral and neurochemical evidence. European Journal of Pharmacology, 2005, 515, 128-133.	1.7	15
48	1,2,3,4-Tetrahydroisoquinoline produces an antidepressant-like effect in the forced swim test and chronic mild stress model of depression in the rat: Neurochemical correlates. European Journal of Pharmacology, 2014, 729, 107-115.	1.7	15
49	Modification of effects of chronic electroconvulsive shock by voltage-dependent Ca2+ channel blockade with nifedipine. European Journal of Pharmacology, 1994, 254, 9-16.	1.7	14
50	1-Methyl-1,2,3,4-tetrahydroisoquinoline and established uncompetitive NMDA receptor antagonists induce tolerance to excitotoxicity. Pharmacological Reports, 2010, 62, 1041-1050.	1.5	14
51	Important role of 3-methoxytyramine in the inhibition of cocaine sensitization by 1-methyl-1,2,3,4-tetrahydroisoquinoline: an in vivo microdialysis study. Pharmacological Reports, 2010, 62, 983-997.	1.5	14
52	Differences between haloperidol- and pimozide-induced withdrawal syndrome: a role for Ca2+ channels. European Journal of Pharmacology, 1995, 294, 459-467.	1.7	13
53	Ca2+ channel blockade prevents lysergic acid diethylamide-induced changes in dopamine and serotonin metabolism. European Journal of Pharmacology, 1997, 332, 9-14.	1.7	13
54	Effect of 1,2,3,4,-tetrahydroisoquinoline administration under conditions of CYP2D inhibition on dopamine metabolism, level of tyrosine hydroxylase protein and the binding of [3H]GBR 12,935 to dopamine transporter in the rat nigrostriatal, dopaminergic system. Brain Research, 2004, 1009, 67-81.	1.1	13

#	Article	IF	Citations
55	Concentration-Dependent Opposite Effects of 1-Benzyl-1,2,3,4-tetrahydroisoquinoline on Markers of Apoptosis: In Vitro and Ex Vivo Studies. Neurotoxicity Research, 2014, 25, 90-99.	1.3	13
56	Antidepressant-Like Effect of the Endogenous Neuroprotective Amine, 1MeTIQ in Clonidine-Induced Depression: Behavioral and Neurochemical Studies in Rats. Neurotoxicity Research, 2017, 32, 94-106.	1.3	13
57	The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA. Neuroscience, 2017, 340, 308-318.	1.1	13
58	Interactions of 1-methyl-1,2,3,4-tetrahydroisoquinoline with lamotrigine, oxcarbazepine, pregabalin, and topiramate in the mouse maximal electroshock-induced seizure model: A type I isobolographic analysis. Epilepsy Research, 2010, 89, 207-219.	0.8	12
59	Antidepressant-like effect of 1,2,3,4-tetrahydroisoquinoline and its methyl derivative in animal models of depression. Pharmacological Reports, 2017, 69, 566-574.	1.5	12
60	Multiple Administration of Endogenous Amines TIQ and 1MeTIQ Protects Against a 6-OHDA-Induced Essential Fall of Dopamine Release in the Rat Striatum: In Vivo Microdialysis Study. Neurotoxicity Research, 2018, 33, 523-531.	1.3	12
61	1MeTIQ Provides Protection Against AÎ ² -Induced Reduction of Surface Expression of Synaptic Proteins and Inhibits H2O2-Induced Oxidative Stress in Primary Hippocampal Neurons. Neurotoxicity Research, 2014, 25, 348-357.	1.3	11
62	The impact of 1MeTIQ on the dopaminergic system function in the 6-OHDA model of Parkinson's disease. Pharmacological Reports, 2016, 68, 1205-1213.	1.5	11
63	Neuroprotective Effect of the Endogenous Amine 1MeTIQ in an Animal Model of Parkinson's Disease. Neurotoxicity Research, 2016, 29, 351-363.	1.3	11
64	Regulation of somatostatin receptor 2 in the context of antidepressant treatment response in chronic mild stress in rat. Psychopharmacology, 2018, 235, 2137-2149.	1.5	11
65	Pro-cognitive effect of 1MeTIQ on recognition memory in the ketamine model of schizophrenia in rats: the behavioural and neurochemical effects. Psychopharmacology, 2020, 237, 1577-1593.	1.5	11
66	Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. European Journal of Pharmacology, 1996, 313, 181-186.	1.7	10
67	Effects of the noradrenergic neurotoxin DSP-4 on the expression of $\hat{i}\pm 1$ -adrenoceptor subtypes after antidepressant treatment. Pharmacological Reports, 2011, 63, 1349-1358.	1.5	10
68	Changes in Monoaminergic Neurotransmission in an Animal Model of Osteoarthritis: The Role of Endocannabinoid Signaling. Frontiers in Molecular Neuroscience, 2018, 11, 466.	1.4	10
69	Synthesis, Physicochemical Properties, Anticonvulsant Activities, and GABA-ergic and Voltage-sensitive Calcium Channel Receptor Affinities of $\hat{1}$ ±-SubstitutedN-Benzylamides of $\hat{1}$ 3-Hydroxybutyric Acid Part 4: Search for New Anticonvulsant Compounds. Archiv Der Pharmazie, 1999, 332, 167-174.	2.1	9
70	Withdrawal from repeated administration of a low dose of reserpine induced opposing adaptive changes in the noradrenaline and serotonin system function: A behavioral and neurochemical ex vivo and in vivo studies in the rat. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2015, 57, 146-154.	2.5	9
71	Comparative behavioral and neurochemical studies of R- and S-1-methyl-1,2,3,4-tetrahydroisoquinoline stereoisomers in the rat. Pharmacological Reports, 2012, 64, 857-869.	1.5	8
72	Repeated Transcranial Direct Current Stimulation Induces Behavioral, Metabolic and Neurochemical Effects in Rats on High-Calorie Diet. Frontiers in Behavioral Neuroscience, 2017, 11, 262.	1.0	8

#	Article	IF	Citations
73	The effect of chronic imipramine and electroconvulsive shock treatment on [3H]DADLE binding to cortical membranes of rats pretreated with chronic reserpine or 6-hydroxydopamine. Pharmacology Biochemistry and Behavior, 1987, 26, 203-206.	1.3	7
74	Differential involvement of voltage-dependent calcium channels in apomorphine-induced hypermotility and stereotypy. Psychopharmacology, 1994, 113, 555-560.	1.5	7
75	Both Stereoselective (R)- and (S)-1-Methyl-1,2,3,4-tetrahydroisoquinoline Enantiomers Protect Striatal Terminals Against Rotenone-Induced Suppression of Dopamine Release. Neurotoxicity Research, 2011, 20, 134-149.	1.3	7
76	1-Benzyl-1,2,3,4-tetrahydroisoquinoline, an Endogenous Neurotoxic Compound, Disturbs the Behavioral and Biochemical Effects of l-DOPA: In Vivo and Ex Vivo Studies in the Rat. Neurotoxicity Research, 2014, 26, 240-254.	1.3	7
77	The adenosinergic system is involved in sensitization to morphine withdrawal signs in ratsâ€"neurochemical and molecular basis in dopaminergic system. Psychopharmacology, 2016, 233, 2383-2397.	1.5	7
78	Comparison of the Effects of Acute and Chronic Administration of Tetrahydroisoquinoline Amines on the In Vivo Dopamine Release: A Microdialysis Study in the Rat Striatum. Neurotoxicity Research, 2016, 30, 648-657.	1.3	7
79	Combined brain Fe, Cu, Zn and neurometabolite analysis – a new methodology for unraveling the efficacy of transcranial direct current stimulation (tDCS) in appetite control. Metallomics, 2018, 10, 397-405.	1.0	6
80	Novel antagonists of 5-HT6 and/or 5-HT7 receptors affect the brain monoamines metabolism and enhance the anti-immobility activity of different antidepressants in rats. Behavioural Brain Research, 2019, 359, 9-16.	1.2	6
81	Plasticity of extrapyramidal dopamine system in Parkinson's disease - A postmortem study. Neuroscience Research Communications, 1999, 25, 97-109.	0.2	5
82	Role of noradrenergic system in the mechanism of action of endogenous neurotoxin 1,2,3,4-tetrahydroisoquinoline: biochemical and functional studies. Polish Journal of Pharmacology, 2002, 54, 19-25.	0.3	5
83	Conditioned rewarding stimulus associated with cocaine self-administration reverses the depression of catecholamine brain systems following cocaine withdrawal in rats. International Journal of Neuropsychopharmacology, 2006, 9, 37.	1.0	4
84	1MeTIQ and olanzapine, despite their neurochemical impact, did not ameliorate performance in fear conditioning and social interaction tests in an MK-801 rat model of schizophrenia. Pharmacological Reports, 2021, 73, 490-505.	1.5	4
85	Serotonin, dopamine, noradrenaline and their metabolites: Levels in the brain of the house cricket (Acheta domesticus L.) during a 24-hour period and after administration of quipazine—a 5-HT2 receptor agonist. Comparative Biochemistry and Physiology Part C: Comparative Pharmacology, 1991, 100, 365-371.	0.2	3
86	Differences in effects of Ca 2+ channel antagonists on dopamine metabolism in the limbic and extrapyramidal dopaminergic structures. Psychopharmacology, 1996, 128, 39-44.	1.5	3
87	Effect of 1-methyl-1,2,3,4-tetrahydroisoquinoline on the protective action of various antiepileptic drugs in the maximal electroshock-induced seizure model: a type II isobolographic analysis. Journal of Neural Transmission, 2013, 120, 1651-1663.	1.4	3
88	Chronic Salsolinol Administration Prevents the Behavioral and Neurochemical Effects of I-DOPA in Rats. Neurotoxicity Research, 2015, 27, 399-410.	1.3	3
89	The Protective Effect of Repeated 1MeTIQ Administration on the Lactacystin-Induced Impairment of Dopamine Release and Decline in TH Level in the Rat Brain. Neurotoxicity Research, 2018, 34, 706-716.	1.3	3
90	1-Methyl-1,2,3,4-tetrahydroisoquinoline – The toxicological research on an exo/endogenous amine with antidepressant-like activity – In vivo, in vitro and in silico studies. Pharmacological Reports, 2019, 71, 1140-1146.	1.5	3

#	Article	IF	Citations
91	Effects of Chronically Administered Antidepressants and Electroconvulsive Treatment on Cerebral Neurotransmitter Receptors in Rodents with â€`Model Depression'. Novartis Foundation Symposium, 1986, 123, 234-245.	1.2	3
92	1-Methyl-1,2,3,4-Tetrahydroisoquinoline: A Potent Neuroprotecting Agent. , 2012, , 45-56.		2
93	Synthesis and Pharmacological Activity of New Carbonyl Derivatives of 1-Aryl-2-iminoimidazolidine. Part 3. Synthesis and Pharmacological Activity of 1-Aryl-5,6(1H)dioxo-2,3-dihydroimidazo[1,2-a]imidazoles ChemInform, 2003, 34, no.	0.1	1
94	Synthesis and Pharmacological Activity of New Carbonyl Derivatives of 1-Aryl-2-iminoimidazolidine. Part 2. Synthesis and Pharmacological Activity of 1,6-Diaryl-5,7(1H)dioxo-2,3-dihydroimidazo[1,2-a][1,3,5]triazines ChemInform, 2003, 34, no.	0.1	1
95	Isoquinolines as Neurotoxins: Action and Molecular Mechanism. , 2012, , 31-43.		1
96	Psychiatric Disorders in Animal Models of Depression. , 2021, , 1-13.		0
97	Antidopaminergic Effects of Putative Endogenous MPTP-Like Agents: 1,2,3,4-Tetrahydroisoquinoline and 1-Methyl-6,7-Dihydroxy-l,2,3,4-Tetrahydroisoquinoline. , 2000, , 105-110.		0
98	1-Methyl-1,2,3,4-Tetrahydroisoquinoline and Addiction: Experimental Studies., 2012,, 57-74.		0
99	Nicotine potentiates imipramine-induced effects on catecholamine metabolism: possible relation to antidepressant activity. Pharmacological Reports, 2006, 58, 836-45.	1.5	O